distribution and therefore used non-parametric statistical tests wherever possible.
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Continuous variables were expressed as the means ± standard deviations, and cases 1 4 0 (VTE) were compared to controls (non-VTE) using Wilcoxon's rank sum test. On the 1 4 1 other hand, categorical variables are presented as number of patients in each group, and 1 4 2 compared using the χ 2 test. In order to compensate for multiplicity in the univariate 1 4 3 analysis, we applied the Bonferroni correction to the α level. 18 After correction, a p value 1 4 4 of < 0.0038 was considered significant in the univariate analysis. For all other analyses, a 1 4 5 p value of < 0.05 was considered significant. To further investigate the PLR, we also 1 4 6 constructed a boxplot to visualize the differences in both groups. The cutoff between a 1 4 7 'high' or 'low' PLR has not yet been unified in the literature. 12, 13 Therefore, we used a 1 4 8 simple linear discriminant analysis (LDA) classifier between PLR and VTE to generate a 1 4 9 receiver operator characteristic (ROC) curve. This ROC curve was used to obtain an 1 5 0 optimal cutoff point for the PLR, and this cutoff point was chosen to maximize both 1 5 1 sensitivity and specificity. A dichotomized PLR variable based on this cutoff was used to 1 5 2 separate patients, and compared with a χ 2 test. The multiple logistic regression model was 1 5 3 performed using the ROC cutoff and other significant variables discovered in univariate 1 5 4 analysis. In the inference stage, we used Firth's penalized method for deriving the 1 5 5 maximum likelihood estimators (MLE) to avoid serious bias due to the sparse events 2 1 1 occurrence of VTE (β 95% CI: 5.3256 -5.3868; p < 0.0001). In addition to PLR, length 2 1 2 of surgery was also found to have an independent association with VTE (β 95% CI: 2 1 3 0.0001 -0.0006; p = 0.0056). The results of our analysis are consistent with published 2 1 4 reports in other cancers in the ambulatory setting by Yang 13 , and Ferroni. 12 These authors 2 1 5 showed that pretreatment PLR was associated with VTE in the ambulatory chemotherapy 2 1 6 setting. In this paper, we have shown that this association is also present in the inpatient 2 1 7 postoperative setting, for HNC patients. Although the results of this analysis are positive, the exact underlying mechanisms 2 2 0 behind the observed association of PLR and thrombosis are speculative. [10] [11] [12] [13] In the past 2 2 1 few years, there has been increasing interest in the tumor microenvironment and its effect 2 2 2 on systematic inflammation. 28 This has led to the study of other biomarkers in addition to 2 2 3 PLR, 29, 30 such as the neutrophil-to-lymphocyte ratio (NLR) 29, 30 and the lymphocyte-to-2 2 4 monocyte ratio (LMR) 31 in HNC prognosis. The 'seed and soil' hypothesis postulates 2 2 5 that the tumor extracellular matrix (ECM) interacts with and is in turn affected by the 2 2 6 inflammatory cells and mediators. 32, 33 Kuss and colleagues had previously demonstrated 2 2 7 that there is altered lymphocyte homeostasis in SCC of the head and neck, resulting in 2 2 8 reductions in all T-cell subsets. 34 Since malignancies have been known to be associated 2 2 9 with thrombotic events, 35, 36 the lymphocyte count might thus be acting as a nonspecific 2 3 0 surrogate for magnitude of the tumor's systemic interaction -and by extension, its 2 3 1 thrombotic potential. 12, 13 2 3 2 2 3 3
On the other hand, the link between platelets and cancer-associated thrombosis has been 2 3 4 well documented. 37-39 By combining the platelet and lymphocytes counts into the PLR, a 2 3 5 crude 'summary effect' between the tumor-induced prothrombotic (platelet) and the 2 3 6 inflammatory states (lymphocyte) is encapsulated. The superiority of the PLR over 2 3 7 platelet count or WBC count alone was demonstrated in our study, in agreement with 2 3 8 other authors. 12, 13 Ferroni and colleagues speculated that increased levels of platelets in 2 3 9 itself could be related to underlying inflammation. In this context, our results were also in 2 4 0 agreement, showing a small but highly significant relationship between the platelet count 2 4 1 and lymphocyte count (R 2 = 0.05, p < 0.0001), and platelet count and WBC (R 2 = 0.08, p 2 4 2 < 0.0001).
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Consistent with other studies, our results also showed that length of surgery was also an 2 4 5 independent predictor of VTE. 40 The association of length of surgery, though highly 2 4 6 significant, was not shown to be as strong as PLR, demonstrated by the marginal β 2 4 7 coefficient. Our results did not show postoperative heparin or aspirin to be associated 2 4 8 with VTE. This could be due to the high amounts of patients already receiving 2 4 9 postoperative VTE chemoprophylaxis in this high-risk cohort -which would therefore 2 5 0 require a much larger sample size to detect a significant difference. There are limitations to our study that we acknowledge. Our study was conducted as a 2 5 3 retrospective cohort study, and as such, is subject to the intrinsic drawbacks of all 2 5 4 retrospective data collection studies. Secondly, our study had a small sample size with The results reported here have shown that PLR has a significant and strong association 2 6 2 with VTE. Current guidelines by ASCO 15 already recommend VTE chemoprophylaxis 2 6 3 for patients with malignant disease undergoing surgery. In the study authored by 2 6 4 Clayburgh et al, 9 they prospectively performed ultrasound scans (USS) for all 2 6 5 postoperative patients and found that the incidence of VTE was much higher than 2 6 6 reported in previous retrospective studies. Drawing from this result, they hypothesized 2 6 7 that a significant proportion of asymptomatic or mildly symptomatic VTEs go undetected 2 6 8 in patients with HNC. Furthermore, Thai and Clayburgh also showed that above the 2 6 9
highest Caprini risk level, there was a failure to discriminate which patients would 2 7 0 eventually develop a VTE. 6, 9 Thus, it is possible that the future utility of the PLR may 2 7 1 be to stratify within high-risk HNC patients -to decrease the clinical threshold in which 2 7 2 to perform diagnostic VTE tests in patients with elevated PLR. 
